Table 2.
Treatment efficacy (N = 36)
| Efficacy | Best overall response |
||
|---|---|---|---|
| N | % | 95% CI | |
| CR | 4 | 11.1 | 3.1–26.1 |
| PR | 11 | 30.6 | 16.3–48.1 |
| SD | 16 | 44.4 | 27.9–61.9 |
| PD | 5 | 13.9 | 4.7–29.5 |
| Confirmed objective response (CR + PR) | 15 | 41.7 | 25.5–59.2 |
| Clinical benefit (CR + PR + SD ≥ 24 weeks) | 27 | 75.0 | 57.8–87.9 |
| Median PFS, months | 8.8 | 6.3–12.3 | |
| Median OS, months | 30.5 | 16.8–NR | |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NR, not reached.